Earnings calls, recall notices not “commercial advertising or promotion,” but could be “of and concerning” largest market player

In re SoClean, Inc., Marketing, Sales Practices &
Products Liab. Litig., 2023 WL 8006602, MDL No. 3021, No. 22-542 (W.D. Pa. Nov.
17, 2023)

Because this is MDL with lots of claims, the facts are a bit
complicated. SoClean is a dominant player in the market for medical devices
that sanitize continuous positive airway pressure machines (CPAPs), which treat
sleep apnea and respiratory conditions. It alleged that the Philips defendants,
who make such devices, engaged in false advertising about one of SoClean’s
devices in order to deflect blame for the Philips devices’ design defects. SoClean
and the FDA have been back and forth about what kind of medical device SoClean’s
product is; as part of their interactions SoClean dropped “claims pertaining to
the cleaning, sanitizing, or disinfection of CPAP machines” from its website.
SoClean has submitted a de novo application for its latest product, which is under
review.

In 2020, the FDA issued a safety communication about
“potential risks associated with the use of ozone and ultraviolet (UV) light
products for cleaning CPAP machines and accessories” focusing only on the issue
of potential risk of ozone leakage, but SoClean alleged that its products don’t
leak ozone at unsafe levels. (In its press release, the FDA referred to its own
testing on “several of those illegally marketed products,” although SoClean
alleged that it believed in good faith that it didn’t need preapproval.)

Meanwhile, Philips allegedly knew for years that the
polyester-based polyurethane foam used to dampen sound in Philips’ ventilator,
CPAP, and other respiratory care devices was susceptible to degradation and
off-gassed potentially harmful volatile organic compounds (VOCs). Philips
allegedly misled the FDA by telling it that foam degradation may be
“exacerbated” by ozone cleaners, without any reliable testing or other valid
scientific evidence to validate those statements. Philips repeated similar
statements elsewhere. One Philips entity’s CEO said, on an earnings call, that
ozone was a problem for foam, and that “[t]he FDA observed this and also put
out a safety notice to say, don’t use ozone for CPAP machines,” which allegedly
misrepresented the reasoning for the safety notice. As in other instances, he
used the opportunity to promote the next-generation Philips product, which had
a more stable foam.

A number of Philips devices were recalled for foam degradation,
giving two reasons to customers and users: foam off-gassing and foam
degradation from use of “unapproved” ozone cleaning devices, which could “exacerbate[e]”
the problem; anti-ozone cleaning claims were disseminated in various ways,
including Philips’ website FAQ about the recall and another earnings call.

Philips also allegedly blamed SoClean at the largest 2021 home
medical equipment trade show and conference in the United States, telling
distributors and resellers during meetings that “SoClean was the problem.” Resellers
and distributors allegedly cited these statements as the reason for not placing
orders with SoClean, leading all but one of SoClean’s top distributors and
resellers to stop placing orders with SoClean.  Because the disparagement was successful, and actual
and prospective customers and distributors believed that SoClean devices were
the reason for the product recall, sales to distributors, resellers, and
end-users allegedly plummeted.

The Philips defendants argued that there was no statutory
Lanham Act standing because they weren’t even indirect competitors, but the
court here found that Lexmark removed any requirement even of indirect
competition (including by blessing lawsuits across the distribution chain, e.g.
manufacturer v. dealer). All SoClean needed was to show that it suffered
commercial injury proximately caused by defendants’ violations of the Lanham
Act, which it plausibly alleged.

However, the Philips defendants argued that SoClean wasn’t within
the zone of interests protected by the Lanham Act because the only commerce
protected by the Lanham Act is lawful commerce. And, they continued, SoClean was
illegally marketing its devices. This argument couldn’t be resolved at the
present stage, when SoClean alleged that it marketed and sold its device “with
the knowledge of the FDA,” including having an FDA inspection of its
manufacturing facility without FDA raising concerns. However, other documents
integral to the complaint indicated that the FDA thought there was a potential
FDCA violation. So the court wanted to hear from FDA experts about whether the
FDA’s knowledge that SoClean planned to continue marketing the challenged
device for a limited period of time gave it a “legally protected interest” during
the relevant timeframe.

Commercial advertising or promotion: A separate problem. Quarterly
reports and earnings calls, “without allegations that defendants intended to
influence the consumers and the communication was disseminated to the consumers,”
aren’t commercial advertising or promotion for these purposes. (The court says
they’re not “commercial speech,” but since that’s a First Amendment term, I’m
using the more statutorily precise “commercial advertising or promotion.”) Here,
the allegations were insufficient to show that the earnings calls and quarterly
report were advertising or promotional; rather, they primarily served their
typical function: to influence investors. Although the statements “may have had
an incidental effect of promoting goods, i.e., to deflect blame for the recall
and promote Philips’ goodwill so that the consumers would continue to purchase
Philips’ devices,” that wasn’t sufficient: they weren’t primarily made to
advertise or promote Philips’ products. Nor did SoClean plausibly allege
sufficient dissemination of the earnings calls and quarterly report; there were
no allegations that any consumers listened to the calls or read the report.

Recall notice: Eli Lilly & Co. v. Roussel Corp., 23 F.
Supp. 2d 460 (D.N.J. 1998), found that a recall notice wasn’t commercial
advertising or promotion because it wasn’t designed to influence customers to
purchase defendant’s goods, but rather to inform consumers that the goods will
no longer be available for sale. Did alleged blame-shifting in these recall
notices change the analysis? No. “[A]ny effect of promoting defendants’
products (by deflecting blame to SoClean to promote the Philips defendants’
goodwill) was incidental to the primary purpose of the recall notice, which was
to inform consumers about the recall.”

Recall FAQ on website: Same thing.

Update to physicians and health care providers: This one
said that “[t]he foam degradation may be accelerated by environmental
conditions of high temperatures and humidity. Unauthorized cleaning methods
such as ozone cleaning may exacerbate potential degradation….” It ended: “Philips
is recommending that customers and patients do not use ozone-related cleaning
products.” Again, this wasn’t an ad but an informational document about the
recall, and it didn’t promote Philips’ newer devices.

2022 press release: The stated purpose of the update was to
“provide healthcare providers, patients, and other stakeholders with updated
information on the testing results to date.” A press release can be an ad, but
not this one. It didn’t promote any Philips product—the only one it mentioned
was the recalled product which could not be sold—or explicitly propose a
commercial transaction. The general economic motive of being a for-profit
business was not enough. “This is not a case in which the press release
compared two products, touted one product as superior to another, or promoted
the defendant’s product.”

Statements to distributors: First, did Rule 9(b) apply? The
court didn’t reach the issue, because even if it did, SoClean could satisfy the
heightened pleading standard by pleading “information and belief” about what
defendants said to third parties.

But were they commercial advertising or promotion, or nonactionable
“oral statements disseminated to a small group of people.” While “purely
private” communications cannot be “commercial advertising or promotion,” this “is
a matter of degree based upon specific facts of a case, including facts about
the pertinent industry.” Here, the allegations about the size and influence of
the trade show, including that the parties’ largest distributors and resellers
were there, sufficed to plead commercial advertising or promotion.

[Pause for harm causation questions: Was too much damage
already done by then? The allegations about losing big distributors after that
seem enough to defeat that argument.]

Falsity/misleadingness: The Philips defendants argued that
the “gist” was true: according to the FDA itself, foam might degrade both on
account of high heat humidity as well as ozone, and customers shouldn’t use ozone
cleaners because they are unapproved, potentially harmful, and might harm their
CPAP devices. The FDA, they argued, was investigating SoClean and issued its
public Safety Communication warning against the use of ozone cleaners more than
a year before the recall at issue in this case, which was more than a year
before the Philips defendants could have allegedly influenced or misled the
FDA.

The court reasoned that SoClean plausibly alleged that the
recall had nothing to do with ozone cleaners or off-gassing during ozone cleaning,
so the statement to resellers and distributors was at least misleading.

New Hampshire Consumer Protection Act: Same analysis. But must
the conduct have occurred in New Hampshire to be actionable? The trade show
wasn’t there. Still, since this was allegedly a nationwide campaign, that was
enough to show plausibly that the offending conduct took place within the
state.

Tortious interference claims also survived.

New Hampshire defamation: The Philips defendants argued that
their allegedly defamatory statements concerned a class of products and how
those products CPAP products, and, therefore, were not “of and concerning”
SoClean. But it was plausible that the alleged statements to the resellers and
distributors specifically referred to SoClean. As for the rest of the
statements (which weren’t covered by the Lanham Act/state consumer protection
law), SoClean plausibly pled that the recipients of those statements understood
that defendants were referring to SoClean. But, defendants argued, SoClean was
really alleging trade libel, not defamation, and trade libel isn’t recognized
in New Hampshire. Still, if SoClean’s own reputation was injured, not just its
product’s reputation, that could be the basis of a defamation claim.

Other issues, like whether SoClean was a limited-purpose
public figure, needed more information; “if SoClean’s devices were legally
marketed and safe (as SoClean alleges) and the Philips defendants provided the
FDA erroneous information about ozone’s role in the foam degradation, then the
controversy would not be about the safety of SoClean’s ozone-generating
devices.”

from Blogger http://tushnet.blogspot.com/2023/11/earnings-calls-recall-notices-not.html

Posted in Uncategorized | Tagged , , | Leave a comment

too much complaining about copying triggers Dastar/preemption for other claims

Design Gaps, Inc. v. Hall, 2023 WL 8103156, No. 3:23-cv-186-MOC
(W.D.N.C. Nov. 21, 2023)

Design Gaps produces custom cabinetry for high-end homes; Hall
is a former employee of Design Gaps who signed a nonsolicitation/noncompete
clause but went to work for a design studio that was part of Design Gaps’ main
competition, Peters. Peters allegedly subsequently constructed homes with
interior designs “substantially similar” to building components depicted in
Design Gaps’ technical drawings. Design Gaps had in the past conducted projects
for Peters Custom Homes including the design and construction of residential
cabinetry in homes referred to as “Quail Hollow North” and “Lake Wylie.” Defendants
allegedly promoted the kitchen and other areas of the residences designed and
constructed by Design Gaps as their own designs and trade dress.

Design Gaps brought trade secret, tortious interference, and
state and federal false advertising/false designation of origin claims against
defendants.

Defendants moved to dismiss the Lanham Act claims as preempted
by copyright. (It’s preclusion, really, but the court says that preemption principles
are implemented by Dastar.) And the complaint was full of references to
Design Gaps’ copyrighted designs and defendants’ “copying.” Here there was
no extra element rendering the claims qualitatively different from copyright
claims. Instead, plaintiffs alleged that the alleged substantial similarity itself constituted
a misrepresentation of origin. This was just Dastar: “Design Gaps does
not allege that the kitchens and cabinets cited in the Amended Complaint were
actually sold in commerce by anyone other than the Peters Defendants.” So too
for the state law claims.

from Blogger http://tushnet.blogspot.com/2023/11/too-much-complaining-about-copying.html

Posted in Uncategorized | Tagged , , , | Leave a comment

who has standing to challenge robot lawyers?

MillerKing, LLC v. DoNotPay, Inc., — F.Supp.3d —-, No.
3:23-CV-863-NJR, 2023 WL 8108547 (S.D. Ill. Nov. 17, 2023)

“This case pits real lawyers against a robot lawyer.” Spoiler:
the robot wins for lack of Article III standing.

DoNotPay is an online subscription service that touts its ability
to allow consumers to “[f]ight corporations, beat bureaucracy and sue anyone at
the press of a button” and bills itself as “The World’s First Robot Lawyer,” offering
legal services “related to marriage annulment, speeding ticket appeals,
canceling timeshares, breaking leases, breach of contract disputes, defamation
demand letters, copyright protection, child support payments, restraining
orders, revocable living trusts, and standardized legal documents.”  But DNP isn’t actually licensed to practice
law. MillerKing, a small Chicago law firm that claims to be a direct competitor
of DNP, sued DNP for false association and false advertising under the Lanham
Act and Illinois state law. Along with state consumer protection claims, MK
alleged that DNP was engaged in the unlawful practice of law under Illinois
law. (The false association claim was based on the theory that consumers are
misled to believe that DNP is affiliated with licensed attorneys and that State
bar authorities approve of or sponsor DNP’s services.)

MK “advertises its services online and provides legal
services across various practice areas including personal injury, wrongful
death, family law, divorce law, child custody, criminal law, traffic law,
estate planning, probate, workers’ compensation, business law, municipal law,
and mediation.” It sought to represent a class of similar law firms.

DNP advertises that it uses artificial intelligence” rather
than “human knowledge.” Users can generate personalized contracts, independent
contractor agreements, non-disclosure agreements, bills of sale, prenuptial
agreements, LLC operating agreements, promissory notes, and parenting plans. It
also touts its ability to give advice on property tax appeal procedures, create
customized property tax guides, provide advice on how to appeal traffic tickets
in any city, provide services to initiate litigation and obtain a judgment, and
guide users through the process of filing a court case. For a lawsuit over
$500, DNP states that it “can generate demand letters, court filings and give
you a script to read in court.” It claims to have taken on hundreds of
thousands of parking ticket cases and overturned $4 million in parking ticket
fines; initiated more than 1,000 small claims lawsuits against a single company
in 42 states; and “processed over 2 million cases.” However, it backed off a
claim that the “robot lawyer” would soon represent someone in a courtroom by
whispering in the person’s ear exactly what to say because of “threats from
State Bar prosecutors.” Some online reviews are poor, stating that DNP has
failed to dispute parking tickets as requested, has created inadequate legal
documents, or has included inaccurate information in its forms. DNP removed
some products from its website, but it continued to advertise and promote legal
products and services including defamation demand letters, divorce
certificates, divorce settlement agreements, and numerous other categories of
legal services.

MK argued that it, and the class, have been or are likely to
be injured by the direct diversion of clients from themselves to DNP or by a
lessening of the goodwill associated with MK and the class’s goods and
services. That wasn’t enough. MK didn’t allege any lost revenue or added
expenditures as a result of DNP’s conduct. Nor did it allege that any MK client
or prospective client withheld business, considered withholding business, or even
heard of DNP. For the hundreds of thousands of parking ticket cases that DNP
claims to have taken on, for example, there was no allegation that those
customers originally were clients of MK, had considered hiring MK, or would
have sought the advice of any law firm in the first place if not for the
representations made by DNP.

As to goodwill, although the complaint alleged that DNP
provided some poor customer service, it didn’t allege that DNP’s failures were
imputed to MK specifically or lawyers generally. What about Lexmark?

Unlike MK, Static Control not only
alleged injury due to diversion of sales and reputational harm, but it also
provided the facts necessary to make those allegations plausible. Static
Control alleged Lexmark directly targeted its customers and falsely stated that
doing business with Static Control was illegal. These facts are sufficient to
state a concrete, particularized, and actual injury. MK’s general allegations
that DNP has caused a diversion of clients and loss of goodwill, on the other
hand, are not.

Even if the Court were to find that MK (a law firm) was a
“direct competitor” of DNP (an AI-based legal subscription service), the court
would not presume Article III standing from direct competition. “MK has
conflated the injury requirement for a statutory cause of action under the
Lanham Act claim with Article III’s injury-in-fact requirement.” Maybe presuming
injury  works in other cases, but the
products here were different enough that the court declined to do so. “[T]he Court will not infer that MK has suffered harm
through lost clients just because DNP has gained them.”

from Blogger http://tushnet.blogspot.com/2023/11/who-has-standing-to-challenge-robot.html

Posted in Uncategorized | Tagged , , | Leave a comment

Holly Herndon and AI in the New Yorker

 Article here. I’m quoted.

from Blogger http://tushnet.blogspot.com/2023/11/holly-herndon-and-ai-in-new-yorker.html

Posted in Uncategorized | Tagged , | Leave a comment

I was on Hard Fork to talk copyright and AI

 Here’s an RSS feed and a Spotify link.

from Blogger http://tushnet.blogspot.com/2023/11/i-was-on-hard-fork-to-talk-copyright.html

Posted in Uncategorized | Tagged | 1 Comment

Nominative fair use: when a logo is not too much

It may well be true that nominative fair use often entails just using a word, not a logo, but courts occasionally recognize that there are situations where the logo/trade dress is actually an important means of communicating and should still fall within nominative fair use. In the wild, that’s usually logos of social media sites, which regularly communicate “this is how to find me” and not “I am endorsed by.” Here’s an example from a competitor that was surely well advised:

Bing Webmaster tools screenshot showing Google search logo on left with invitation to import settings from Google

from Blogger http://tushnet.blogspot.com/2023/11/nominative-fair-use-when-logo-is-not.html

Posted in Uncategorized | Tagged | Leave a comment

when can pharma experts testify about compliance with the FDCA? (also some survey stuff)

ImprimisRX, LLC v. OSRX, Inc., 2023 WL 7390842, No.
21-cv-01305-BAS-DDL (S.D. Cal. Nov. 8, 2023)

Imprimis sued defendants, competitors in the compounding
pharmacy industry, for false advertising, trademark and copyright infringement,
and related claims. It alleged that defendants falsely advertised that they’re
in compliance with Section 503A of the FDCA, governing compounding.

The court here admits the parties’ experts.

Imprimis’s trademark survey expert (for secondary meaning)
didn’t use a control group, but that went to weight rather than admissibility
in the absence of other serious problems. The survey targeted an appropriate
population (ophthalmologists and optometrists as confirmed via a series of
employment questions), used a standard question format, provided a “don’t
know/have no opinion answer,” excluded respondents who answer questions too
quickly, randomized the questions, and surveyed an appropriate population size.
Nor did failure to address genericity render the survey inadmissible.

Another expert surveyed prescribers to opine on the extent
to which a company’s advertising claim that it operates in full compliance with
Section 503A is important to them. In the closed-response survey, the expert included
a question asking whether it would be “important to [respondents] when
selecting a compounding pharmacy” that the “Pharmacy is in compliance with
local zoning requirements” as a control question: Respondents that selected
this question were removed from her final estimates. Whether this control
adequately accounted for noise went to weight rather than admissibility. Again,
there weren’t other serious problems.

Defendants argued that the expert didn’t evaluate the
advertising at issue—the survey didn’t ask whether the “small-font claim” on defendants’
actual webpage would be important to prescribers in their purchasing decisions.
Using hypotheticals rather than the exact statements at issue went only to
weight; it was still relevant to materiality.

Defendants also argued that the survey’s results were
logically contradictory and thus fundamentally flawed. Although 54.1% of survey
respondents selected “Pharmacy operates in full compliance with Section 503A
regarding compounded drugs” under the FDCA as an important factor in selecting
a compounding pharmacy, in a separate question, 57.4% of survey respondents
answered they were not aware of Section 503A prior to taking the survey. Again,
this went to weight rather than admissibility unless “a survey’s results are so
illogical as to cast doubt over its reliability, the inquiry can move from
weight to admissibility,” which didn’t happen here.

The results were logically possible: “Prescribers can
maintain a preference that compounding pharmacies follow all applicable rules
and regulations without having an awareness of all the applicable rules and
regulations.” Also, the control question attempted to isolate Section 503A’s
importance relative to other, hypothetical regulations. Finally, “even if the
response is irrational where a respondent believes Section 503A compliance was
an important factor in selecting a compounding pharmacy but is unaware of
Section 503A, the assumed percentage of irrational responses is not so
significantly pervasive as to morph the issue from weight to admissibility.”

Plaintiffs also designated an expert on pharmacology and
pharmacy operations to opine on what compound medications are, what the
differences are between Section 503A and Section 503B facilities, what
restrictions govern Section 503A pharmacies, whether defendants operate in
compliance with Section 503A regulations, and why compliance with Section 503A
regulations is important.

The proposed expert was qualified: he was clinical faculty
at the University of California San Diego School of Pharmacy and Pharmaceutical
Studies where he teaches classes in pharmacy law and ethics, among other
things. Although he wasn’t a licensed attorney, “his practical and academic
experience with compounding regulations qualifies him to offer his opinions
about compliance with Section 503A regulations.” And his expertise would assist
the jury: he was interpreting the evidence for whether defendants were filling
bulk orders in contravention of Section 503A and evaluating their suggestions
for order volume according to his familiarity with industry norms and
practices.

But did he offer impermissible legal conclusions? “The Ninth
Circuit has previously allowed expert testimony about compliance with industry
standards and regulations, where that testimony does not reach the ultimate
issue of law, even if that testimony was couched in legal terms.” This depends
a lot on exactly what the expert says. Here, he wouldn’t be allowed to present
statements such as “OSRX routinely violates the rules … of 503A pharmacies,”
but he could testify to his opinions on how to understand Sections 503A and
503B regulations and apply those industry norms, regulations, and practices to
the facts at hand.

Defendants’ proposed expert on the same topic got in too.
She didn’t need to be a statistician to testify that “OSRX routinely dispenses
its compounded drugs pursuant to valid patient-specific prescriptions, as
required under section 503A of the [FDCA].” She had “the requisite exposure and
experience to select a simple subset of prescriptions to review and is
qualified to opine on the subject matter as an expert witness under Rule 702.” But,
like plaintiff’s expert, she would not be allowed to say “OSRX’s dispensing
practices are compliant with 503A pharmacy requirements.” Instead, she could
testify about her review of OSRX’s prescription data and whether defendants
appear to prescribe products in bulk. Her review of the records would assist
the jury in understanding whether a valid prescription was present for each
allegedly bulk order/office stock, which a layperson would struggle to do.

 

from Blogger http://tushnet.blogspot.com/2023/11/when-can-pharma-experts-testify-about.html

Posted in Uncategorized | Tagged , | Leave a comment

alleged Haitian corruption doesn’t make collection of “foreign taxes” misleading or material

Celestin v. Martelly, — F.Supp.3d —-, 2023 WL 6385 (E.D.N.Y. 2023)

Plaintiffs alleged Martelly, the then-President-elect of
Haiti, devised a “wide-ranging scheme” to impose fees and fix prices on money
transfers, food remittances, and international calls made to and from Haiti.
Martelly allegedly “promoted, marketed, advertised and sold” the Fees to the
public as necessary “to finance free education for impoverished children,”
knowing that wasn’t true: a program to fund free education in Haiti allegedly
does not exist. While the Government of Haiti purports to receive at least an
estimated $132 million per year from the Fees, there was allegedly no public
accounting.

The Sherman Act claims failed because they were antitrust
claims.

State law deceptive advertising claims were based on the
following statements:

1. “$1.50 and $0.05 added to money transfer and telephone
calls to Haiti are lawful taxes/fees imposed to raise revenue to fund free
education.”

2. “Taxes imposed to finance free education.”

3. “For all transfers, Receivers may receive less due to
foreign taxes.”

4. “Recipient may receive less due to fees charged by
recipient’s bank and foreign taxes.”

First, the plaintiffs didn’t allege the corporate defendants
(telecom/transfer companies) made any representations at all about the fees;
“recipient may receive less due to foreign taxes” was a generic disclaimer that
didn’t say anything about the lawfulness or validity of Haiti’s fees and was,
indeed, true. Nor did the allegations show that corporate defendants knew of
the education falsity. As for the rest, there was no allegation of reliance. “Moreover,
it is unclear how the education plan could be material in Plaintiffs’ decision
to send money or make phone calls to Haiti.” Indeed, the plaintiffs continued
to send money and make phone calls to Haiti despite their knowledge that the
funds are being misused.

FDUTPA specifically only applies to actions within Florida,
which weren’t sufficiently alleged.

 

 

from Blogger http://tushnet.blogspot.com/2023/11/alleged-haitian-corruption-doesnt-make.html

Posted in Uncategorized | Tagged , | Leave a comment

(c) infringement and false advertising claims against addiction treatment competitor survive, in part

New Directions Program v. Sierra Health & Wellness
Centers LLC, 2023 WL 7284797, No. 2:22-cv-01090-DAD-JDP (E.D. Cal. Nov. 1,
2023)

Plaintiff Gust is the “principal and owner” of plaintiff New
Directions and “has been an expert in the field of treatment of addiction and
intoxication for decades.” Gust allegedly “developed an outpatient treatment
model based on the principle of addiction as a pathological relationship to
intoxication rather than as a preference [for] a specific drug.”

One of Gust’s students was Daily, the founder of defendant
RHCS (now owned by Sierra); when he passed away, his wife—also a defendant—took
over. Plaintiffs allege that defendants falsely claimed credit for the “Gust
method,” and infringed the copyright in Gust’s book Effective Outpatient
Treatment for Adolescents by using copies with clients, copying two appendices
for a recorded presentation, and copying the book in a brochure listing six
stages of recovery that are identical to those described in the book.

The court first found that the Lanham Act claim was grounded
in fraud and had to satisfy Rule 9(b).

Challenged statement: “Jon Daily’s legacy will continue as
[Sierra Health and Wellness] will keep all of their intensive outpatient
program with the name Recovery Happens and his model of care.” This was
allegedly false because “Jon Daily had no model of care” and used the Gust
model. (Those two statements are arguably in some tension.) The “when” was
insufficiently alleged, so the court didn’t inquire further.

Challenged statement: “Sierra Health and Wellness and New
Start Recovery Solutions are proud … to offer the compassionate, insightful
and whole person outpatient addiction treatment philosophy founded by Jon
Daily.” The court found plaintiffs plausibly alleged that the addiction
treatment philosophy at issue was not, in fact, founded by Daily, and that
consumers would have no reason to doubt this claim. Materiality was also
sufficiently pled; the court credited plaintiffs’ argument that being connected
to “the legacy of an innovator in the field” makes it more likely that a
product will be chosen by consumers and makes defendants seem “more
substantial, credible and credentialed.” Plus, plaintiff Gust “practices in the
same building as [the moving defendants],” so “even minor perceived differences
between the two practices could plausibly influence consumers’ decisions.”

You may be wondering: what about Dastar and Sybersound’s
extension of that reasoning, which is binding on this court? So is the court!
It wasn’t going to evaluate the issue sua sponte, but it suggested that
plaintiffs be prepared to address the Dastar issues if they amended the
complaint. (Presumably it should feature in the answer as well.)

Challenged statement: in a section titled “the relevance of
Jon Daily,” defendants’ websites state: “ ‘ADDICTION is a PATHOLOGICAL
RELATIONSHIP to INTOXICATION.’ ” But Gust allegedly “developed the concept of
‘addiction to intoxication’ years before Jon Daily even entered the field.” Plaintiffs
plausibly alleged misleadingness in giving Daily credit for that idea, and
materiality for the reasons noted above.

 Challenged statement:
Daily “believed that individuals become addicted to INTOXICATION as a way of
dealing with life issues. If you remove the drug—the individual who is still
addicted to intoxication will find another way to get high. For example, by
using another substance or activity such as sex or gambling.”  Plaintiffs alleged that these “are all words
that David Gust taught for many years” and that “[a]ttribution to Jon Daily is
false and misleading ….” This wasn’t sufficiently alleged to constitute
deceptive attribution to Daily as innovator.

Challenged material: a video in which Daily “uses the Gust
phrase ‘Addiction to Intoxication’ ”; Gust’s book “can be seen on the video”;
Daily “makes a statement that … is clearly just [Chapter 1 from plaintiff
Gust’s book, “How to Help Your Child Become Drug Free”], repurposed”; and Daily
had “taken verbatim” plaintiff Gust’s “old series of projector slides” to use
as his own PowerPoint slide headers without attribution. Again, plaintiffs
didn’t sufficiently allege deception/that Daily claimed to have created the
ideas.

Other statements dismissed as puffery: “ ‘Exceed the
expectations of our clients’, ‘World Class’ and ‘Unlike any other in Northern
California.’ ” as well as statements that defendants use “evidence based
methods.”

Copyright: For the book, plaintiffs didn’t allege facts
indicating that defendants engaged in direct copying or unlawful
appropriation.  It was not enough to
allege conclusorily that “defendants have copied portions of this Book and have
used and published copies of portions of this book including copying and using
treatment documents with clients ….”

DVD: The question was whether plaintiffs sufficiently
alleged probative similarity between defendant’s DVD and two appendices to the
book, “the core of the intervention phase of the Gust model.” Plaintiffs alleged
that Gust’s book “describes the main topics explored in [the Gust] process as,
‘School, Family Relationship, Motivation, Legal Issues, Friendship and Social
life, Employment, Finances, Physical health, self image/self respect/emotions,
Additional examples’ ” And the DVD allegedly uses a slide that reads “ ‘self
inventory: where to explore in the process’ ” and lists the following
categories: “ ‘Family, Money, School, Sports, Legal Issue, Health, Mental
Health, Friends, Self, Spirituality, Sexuality, Additional Examples.’ ” This
allowed a reasonable inference that there wasn’t independent creation. “These
similarities and unusual features are not de minimis and permit the court to
draw the reasonable inference that the two lists are substantially similar
under the extrinsic test. The court need not engage in the application of the
intrinsic test in considering a motion to dismiss.”

A similar result on the brochure, where the overlap was in
describing the six stages of recovery: Recognition, Admission, Petition,
Acceptance, Volition, Conversion. I really can’t believe that should be
sufficient, but I recognize that in the Ninth Circuit there is essentially no
minimum boundary for actionable copying before, at least, summary judgment if a
factfinder could actually see the similarity.

 

from Blogger http://tushnet.blogspot.com/2023/11/c-infringement-and-false-advertising.html

Posted in Uncategorized | Tagged , , | Leave a comment

Artistic Expression or Crass Commercialism? Drawing the lines in Right of Publicity, Lanham Act, and Commercial Speech Cases

PLI Media Law conference

RT: There’s been a rapid and somewhat disorienting shift
from a seemingly ever-growing First Amendment freedom of speech to a seeming
indifference to speech and press based claims (as contrasted to religious
freedom claims) in many categories, concentrated in the sudden conservative
abandonment of the commercial speech doctrine. Historically, conservatives
opposed the commercial speech doctrine, which held out the prospect of greater
regulation of commercial speech than of noncommercial speech. However, as
conservatives identified commercial speech, or even just corporate speech and
practices, they’d like to regulate as being too woke, and in line with
populist, anti-monopoly principles, a number of judges, including judges from
varying political backgrounds, have signaled their lack of interest in free
speech claims, whether made against copyright, trademark, false advertising, or
right of publicity lawsuits. Although the Court long ago recognized that
defamation claims need First Amendment safeguards because the state, through
the judiciary, is making rules for speech, it is now unwilling to recognize the
need for similar limits on other causes of action.

 I’m going to talk briefly about last term’s Jack Daniels
case—a trademark infringement and dilution case—as well as Elster, argued last
week, in which the Justices appeared inclined to reject a First Amendment
challenge to the refusal to register the claimed mark “TRUMP TOO SMALL” for
t-shirts. Then I’ll talk about the 9th Circuit case Enigma Software
v. Malwarebytes, which allowed a false advertising claim to proceed based on
one software provider’s use of the terms “malicious” and “threat” to describe
its alleged competitor’s software, despite a dissent raising free speech
arguments. I’ll conclude with some general remarks about commercial speech
doctrine after 303 Creative and the pending NetChoice cases. 

Trademark: In Jack Daniel’s v. VIP Products, the Court held
that it did not need to apply or even decide the validity of a
speech-protective limit on trademark law designed to prevent trademark owners
from shutting down expressive works that comment on trademarks, known as the
Rogers test.  So long as the defendant
was using a similar term as a trademark to brand its own goods (here, dog toys
that parodied Jack Daniel’s well-known whisky bottle), trademark law’s test for
consumer confusion was all that was required. The First Amendment offered no
further protection for this speech, even though the Court did not categorize it
as commercial speech, and it would not have qualified as commercial speech
under ordinary standards.   The Court did
not decide whether the First Amendment offered any protection against trademark
infringement claims even for purely expressive noncommercial speech, as every
circuit to have considered the issue had held.  
But three Justices wrote separately to express their skepticism that
even purely expressive noncommercial speech involving trademarks merited a
speech-protective test, basing their argument on the fact that the statute did
not specifically outline such a test.

 The Court’s conclusion that a defendant’s use as a trademark
obviates the need for any further consideration of the First Amendment makes
sense, if at all, only as a strong form of the rule that commercial speech
receives significantly less protection that other forms of speech, combined
with an incredibly expansive definition of commercial speech. In Jack Daniels,
the Court claimed that the likely confusion test “does enough work to account
for the interest in free expression” in the context of trademark uses.  This language, as others have noted, is very
similar to its previous statement in Eldred that fair use and the
idea/expression distinction internal to copyright law provide all the First
Amendment protection necessary in the context of copyright infringement.   But in Eldred, the Court followed its
statement by explaining that the Copyright Clause provided a robust foundation
for federal copyright, and that the contemporaneous adoption of the Bill of
Rights and the first federal copyright act showed their compatibility. In Jack
Daniels, the Court said nothing further; its statement remained ipse dixit. Nor
could the court have said more: There is no Trademark Clause and no Founding
Era federal trademark law; indeed, the Court invalidated Congress’s first
attempt, nearly a century later.  And
what current courts call “likely confusion” would be unrecognizable to
Founding-era courts—or post-Reconstruction courts—both of which protected
trademark owners in far more limited circumstances: only in cases of “passing
off,” where the defendant’s goods would substitute for purchases of the
plaintiff’s goods. Current confusion doctrine is very different in many ways,
two of the most important being, first, that there is no materiality
requirement—consumers need not care at all about the thing they’re supposedly
confused about, and that itself makes confusion easier to find because people
aren’t careful about things they don’t care about. Second, modern confusion
covers not just confusion over the source of goods or services but, in many
cases, confusion over whether the plaintiff’s permission was required or
whether there is some sort of undefined “affiliation” between the parties. The
Court’s statement that the likely confusion test provides the only necessary
protection for the First Amendment thus lacks either the explanatory apparatus
it offered in Eldred or a basis in text, history, or structure.

 Where, then, is the sufficiency of likely confusion from? It
has long been true that the First Amendment assigned no value to “false
statements of fact,” justifying restrictions on deceptive commercial
speech.  But, as I’ll discuss more in a
moment, it is possible to turn almost any objection to speech into the claim
that the speech is misleading. Jack Daniels suggests that speech might get no
First Amendment protection against claims labeled “trademark” claims beyond
whatever dubious safety a multifactor likelihood of confusion test may provide—something
that generally requires expensive litigation to work out.  The Court also revived Jack Daniel’s dilution
claim, which was not based on any falsity or risk of confusion but on the
theory that being associated with dog poop would “tarnish” the consumer image
of Jack Daniel’s even though consumers understood that there was no relation
between the companies. 

 Last week’s oral argument in Elster highlighted both the
Justices’ skepticism about free speech claims in the trademark realm and their
lack of interest in the realities of litigation. The Court seems likely to
uphold the prohibition on registering TRUMP TOO SMALL without Trump’s consent,
even though the use isn’t confusing. This will be based on the assertion that
Elster has the right to use TRUMP TOO SMALL on the front of t shirts even
without a registration, and that he couldn’t be prohibited from doing so. But,
if the Court also says there is a legitimate interest in prohibiting
source-indicating uses of an unconsenting person’s name, then that will suggest
a more formalist version of what counts as a trademark use. 

Consider for example this argument by Gov’t: “As long as
[Elster] can use the expression and as long as he can obtain the benefits of
trademark registration by choosing a different source identifier to distinguish
his goods from others, he has all he needs [for his free speech]”

 This concept of source identifiers is very important: it has
to be somewhat normative if we are preserving his ability to use the
expression. The limit case is when TM owners convince 15% or more of consumers
that any reference to them at all requires permission—the Court seemed
unwilling to deal with that scenario, which fits the facts of a number of the
Rogers cases it distinguished in JDI where the court simply declared that song
titles and movie titles weren’t being used as indicators of source.

 Everything here turns on what the Court understands source
identification to mean; if any use that causes any confusion about anything is source-identifying,
then the Court will be allowing huge amounts of speech suppression, but if it
adheres to the idea that trademark, source-indicating use can be objectively
identified and doesn’t exist merely because there’s some kind of confusion,
that can point the way to a workable regime.

 My main worry is that the Justices have no interest in the
fact that lower courts have routinely considered the existence of confusion
about something, including about whether the TM owner gave permission for an
accused use, as proof of trademark use.

 For example, Justice Jackson said: “trademark is not about
expression. Trademark is not about the First Amendment and … people’s ability
to speak. Trademark is about source identifying and preventing consumer
confusion.”

 That has to be a normative concept of source identification!
And it’s incoherent without more (if things are confusing, it’s because they express
a message about source or sponsorship; Justice Jackson has to mean that
trademark infringement is not about protected expression—but that doesn’t
really explain what trademark registration is about).

 The Court’s indifference to expressive elements of TMs also
conflicts with the Court’s previous claims in Tam, and even Jack Daniel’s, that
TMs themselves often have lots of non-source-indicating expressive meaning:
Jack Daniels isn’t just a piece of information, it is a lifestyle and brand
identity—but then shouldn’t people be able to criticize that identity if they
aren’t making false claims?  Court can’t
seem to figure out how to handle that duality between pure information and
brand value.

 The Court’s First Amendment jurisprudence in IP may reflect
its current preoccupation with legislative over judicial restrictions on
speech.  The legal realists taught us
that an injunction issued by a judge and enforced by the threat of prison is
every bit as much state action as an ordinance passed by a city council. But
the Court today seems much less concerned about courts actually ordering people
not to speak. The Court’s willingness to see threats to speech in the
government’s refusal to register trademarks but not in the government’s banning
the sale of products bearing messages altogether suggests that the imperial
judiciary is alive and well in the First Amendment arena.

 Turning to Enigma and false advertising: Commercial speech
doctrine has generally treated false or misleading commercial speech as
completely unprotected by the First Amendment (with some wiggle room for speech
that might be correctable with further disclosures). The attack on commercial
speech doctrine has historically focused on preventing government regulation of
non-false advertising—speech that might encourage unwise consumption of alcohol
or tobacco, for example. Thus, commercial speech doctrine got closer and closer
to strict scrutiny if the government was regulating outside of the false
advertising context, but remained relatively lax if the government was
targeting deception.

 But this sharp cliff between types of regulation puts a
premium on being able to distinguish false and misleading speech from speech
that persuades people to do unwise things. This has always been a weak point:
if you defer to the government on what is misleading, then the government can
regulate a lot of commercial speech, even if most people are persuaded rather
than misled. A few Terms back: NIFLA said that these rules didn’t apply to
antiabortion counseling, even with evidence that clients were misled about what
these antiabortion services did. And some people took that as a signal that
mandatory disclosures generally were in trouble, though I was never
particularly persuaded: my own view is that abortion rules are special and the
Court ignores the ordinary First Amendment analysis in abortion cases.

 Enigma is a useful test case because it sounds like a
standard false advertising case: the parties allegedly compete (though the
defendant doesn’t agree that they do) and its software labeled the plaintiff’s
software as a potential threat or potential malware. Although the Ninth Circuit
majority acknowledged that there’s a lot of judgment involved in deciding what
is malware, it rejected the defendant’s argument that threat or malware were
nonactionable opinion, in the context of threat defense software. A dissent
argued that this was classic opinion, given the ambiguities in the definition
of malware, which can include stuff that’s just not helpful. And I tend to
think that we should be willing to find falsifiability where the advertiser
claims some kind of expertise in the field, even if we shouldn’t find ordinary
users’ characterizations of something as malware to be potentially defamatory.
But it’s also useful to note that Enigma applied the Lanham Act, which bars
false or misleading commercial advertising generally, rather than legislatively
or administratively identifying a more specific practice. Thus, case by case
adjudication in court is required to find deception. By contrast, a district
court in Colorado last week granted antiabortion activists the right to
advertise “abortion reversal” despite an legislative finding that there is no
such thing—because the drugs at issue could lawfully be administered for other
conditions, the activists had free exercise rights to promote them for abortion
reversal. Of course the situation isn’t exactly the same, but it’s indicative
of where judicial deference is going—to people making religious claims and not
to legislatures making findings of fact.

 Compare the question: can one lawfully advertise conversion
therapy to change a young person’s sexual orientation? NJ case a few years back
allowed false advertising claims against the advertiser to proceed. But: If the
government can decide that the promise of conversion therapy is false, can a
different government also decide that it is false and misleading to offer
gender affirming care to trans youth? If you think that the problem is that
this issue is too politicized to allow one side to be labeled false, consider
how many other things have become politicized, and will be politicized if one
party acts. One recent Major area of contestation has been: vegan meat and
dairy substitutes. Meat-producing states have tried to declare that it’s
inherently misleading to use terms like chik’n or sausage, or even oat milk.
Courts so far have struck those down because in the courts’ own views the terms
aren’t misleading—but there are surveys out there that say otherwise for a
nontrivial number of consumers. In addition, the real problem with the vegan
alternatives is that they often have a very different nutritional profile;
there are tragic cases of children who have suffered diseases like kwashiorkor
because their parents were feeding them only vegan alternatives. And the
evidence is very clear that ordinary consumers do not understand the nutritional
differences between almond milk and cow’s milk. Does that mean a ban on the
term “almond milk” is justified?

 The usual response is to punt to disclosures: we’ll fix this
problem by telling people the nutritional content is different! Information
overload makes this less effective; the very power of the term “milk” as a cognitive
shortcut tends to lead people to believe they don’t need to know any more,
meaning that they ignore additional information. So in fact you may not be able
to solve the problem with more disclosures. But they’re politically palatable
in ways that bans usually aren’t, so disclosures are a popular solution.

 They can also be incredibly burdensome, often not because of
the costs of publicizing the disclosure itself but because of the record
keeping that needs to be done. For example, keeping records to ensure that all
one’s contractors feed cows organic feed can be difficult, as can identifying
the country of origin of each head of cattle if it’s cheapest to just commingle
them in huge lots. And here we arrive at the latest wrinkle in Commercial
speech doctrine generally:

 NetChoice: Texas and Florida, explicitly trying to punish
companies perceived as being too liberal, enacted burdensome requirements on
large social media companies. I’m not going to discuss the viewpoint neutrality
mandate, but both states also ordered social media companies to provide
detailed information to users about every moderation decision they made, with
risks of substantial penalties for every error or failure to disclose enough
information to satisfy the states’ AGs. The 11th Circuit struck this
compelled speech down even using intermediate scrutiny, while the 5th
Circuit held it was an unremarkable disclosure mandate regulating commercial
speech. The key move made by the 5th Circuit was to treat all
content policies as commercial speech, which also suggests that the Washington
Post’s editorial policies are commercial speech. Of course, the point was to
make it extremely expensive, burdensome and risky to moderate content, with the
predictable result that companies would do a lot less moderation, so here we
have disclosure that is defended as protecting consumers—so they’ll know what
the actual terms of service are and how they’re enforced—but actually enacted
to change the underlying content policies. Nor are liberals immune from this:
Washington DC’s AG is seeking to get information about individual facebook
accounts to make a claim about its actual policies on covid denial being other
than they were supposedly advertised to be.

 I hesitate to make predictions here but I posit to you that
a Court that no longer sees the point of protecting nonreligious speech, or no
longer sees media entities as having their own speech interests distinct from
those of their users, is going to be dangerous for media freedom far beyond
intellectual property claims.

 Bennett Cooper (Bad Spaniels/VIP): Without a safe harbor, we
have to fight hard on the confusion arguments on remand. We are confident in
that, as well as a challenge to the viewpoint discriminatory nature of dilution
by tarnishment. You have to sell the joke: if the courts don’t get it, you’re
having a harder time: Kagan didn’t get the joke.

 Panel Leader: Jeremy Feigelson: Is the 1A in trouble when
courts avoid doctrine and say “this is just a TM case”?

 A: We’ll have to see. Speech as its own category/do other
categories take free speech into account, for example if the multifactor test
can offer true speakers offramps from the multilane highway of litigation, that
can help.

 Bruce Johnson: Commercial speech doctrine is becoming more
uncertain as a category. NetChoice cases are compelled editorial transparency;
both 11th and 5th Circuit used commercial
speech/Zauderer, which is the weakest test available. It only applies to ads!
Why use this category to interpret compelled editorial transparency? Baffling!
Unclear to what extent we’ll have commercial speech as a separate doctrine, as
opposed to “Zauderer for speech we don’t like.” AG pressures: efforts to
prohibit Yelp users from communicating about crisis pregnancy centers, using
the Little FTC act in Texas. Washington/Value Village case: if we can squeeze
this into commercial speech, we can regulate the hell out of it. Users were
commenting about things protected by 1A until Ken Paxton decided that wasn’t
ok. Making commercial speech law incoherent.

 Jennifer Rothman: Commercial speech doctrine has been
eroded/diluted over decades. Part of a larger story of Court deferring to
property rights over speech. After Jack Daniels we have questions and concerns
both within TM and 1A. Rogers is important to a variety of creative industries
that have relied on it for references to identities/marks. Court clearly
signals that it doesn’t love Rogers, but they didn’t make a bright line about
use as a mark. But that’s also true of Rogers itself, where Ginger Rogers’ name
was incorporated into the movie title itself, which seems to function at least
in part like a source identifier (contingent on identifying a particular
creative work, which because of copyright law will be from a particular source
for a while).

 Thinks the lower courts will still gravitate to Rogers in
traditional expressive use cases, not product cases. But products can be
expressive, some will say! Still, courts are going to draw lines. Not really a
comment; using value of mark to make a joke, which is generally disfavored. We
may see less destabilization b/c courts are still going to prefer/protect
traditional expressive uses and not “commercial products.” But this also
destabilizes defenses to ROP claims, in conjunction with Warhol, b/c some courts
have also relied on Rogers in ROP cases. To the extent that Warhol calls
transformativeness into question v. market harm, states like California that
use transformativeness in 1A defenses to ROP will also see those destabilized.
Finally, dilution: doesn’t think Court shares her (or RT’s) concerns—dicta
suggests that Court will find dilution by tarnishment ok, even if it seems
viewpoint-based.

Johnson: Bigelow v. VA was an abortion speech case; Court
went out of its way to protect commercial speech where something was legal in
one state and illegal in another; we’ll see more efforts pushed on whether and
to what extent speech is purely commercial or whether there are expressive
rights underneath it.

Feigelson: connection to 303 Creative?

A: decided on slender record; Court went out of its way to
protect website developer from being compelled against her will to respond to a
person who allegedly called her and wanted to have a gay wedding website; this
doesn’t seem to be true but the Court still said she didn’t have to provide
service. Court eliminated Colorado’s disclosure requirements too. Zauderer
requires you to provide corrective speech where your affirmative commercial
speech would otherwise be misleading; but the test is “purely factual/noncontroversial,”
and that doesn’t seem to apply here.

Feigelson: Elster: is Court going out of its way to limit
the First Amendment?

A: not really what the case is about—don’t overcommit to
preliminary interpretations. But they were suggesting that the free speech
interests weighed in the other direction: allowing one registration of Trump
Too Small could prevent other criticism of Trump b/c Elster could block
competitors. There are some arguments that the 1A weighs against registration
here [though will the Court recognize that with other registrations?]. Other
connections: 2(c) bar is about gov’t interest in protecting individual identity—“longstanding”
protections for individual identities in TM law. This is an instance where you
don’t have to show likely confusion about sponsorship/endorsement. That
suggests again the Justices’ willingness to allow claims not rooted in showings
of likely confusion—which would be helpful for dilution’s survival.

Cooper: These cases are on a spectrum: viewpoint
discrimination v. neutrality; whether you’re talking about the right to have a
good name v. effectiveness as a source identifier. Tam/Brunetti found viewpoint
discrimination, whereas 2(c) is viewpoint-neutral [except in combination with
2(a) and 2(d)]. Tarnishment situation is more like Tam/Brunetti, because you’re
talking about banning nonconfusing uses with a particular viewpoint. 2(c)’s
consent requirement is more about source identification: worry about potential
endorsement/connection. Blurring is about effectiveness of mark as wayfinder in
marketplace; the Court might favor that b/c it’s closer to TM’s function.
Tarnishment is a “happy talk” provision.

Turning to ROP:

Rothman: Writers’ strike is settled; actors continue—they
seem close on residuals, pay structure, streaming. But still outstanding in
external reporting is AI provisions. Concerned about studios/producers scanning
actors and reusing them w/out control or payments.

Lots of legislation proposed furthering particular parties’
interests, including NO FAKES act—resurrecting James Dean—deceased performers
could replace work for the living, and we don’t necessarily want to create more
robust rights in the dead to allow that replacement to take place. SAG/draft
legislation hasn’t addressed need for disclaimers/revealing to the public that
the actual person had nothing to do with the work, which could be important far
beyond creative industries.

Originally NO FAKES was fast-tracked, sponsored across party
lines. But it turned out not everyone could agree on it.

Feigelson: should Enigma cause worries about product
reviewers?

RT: depends on how integrated you are with your sponsors. If
you are heavily integrated, then disclosure at a minimum is required. And if
you’re making health claims then yes you should worry. But Wirecutter is
unlikely to be treated as commercial speech—that’s a product review.

Johnson: “threat” and “malware” would be 1A protected
opinion in most circumstances; the 9th Circuit found them suspicious
b/c a competitor used those terms—an exception created when it’s not quite
commercial speech (footnote says that it wasn’t clear this was commercial
speech; that was for remand). Liability wouldn’t arise in a pure op-ed.

 

 

 

from Blogger http://tushnet.blogspot.com/2023/11/artistic-expression-or-crass.html

Posted in Uncategorized | Tagged , , , , , , | Leave a comment